QQ客服 官方微博 反馈留言

	Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity
	Liu, M.; Li, W.; Larregieu, C.A.; Cheng, M.; Yan, B.; Chu, T.; Li, H.; Mao, S.-J.
刊名	Molecular Pharmaceutics
	2014
卷号	Vol.11 No.7页码:2305-2312
关键词	acute myeloid leukemia (AML) daunorubicin drug targeting liposome low density lipoprotein receptor (LDLR)
ISSN号	1543-8384
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/1817473
专题	四川大学
作者单位	1.a Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, Sichuan University, No.17, Southern Renmin Road, Chengdu 610041, China 2.Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People Hospital, Chengdu 610072, China 3.Department of Bioengineering and Therapeutic Sciences, University of California - San Francisco, San Francisco, CA 94143-0912, United States 4.Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
推荐引用方式 GB/T 7714	Liu, M.,Li, W.,Larregieu, C.A.,et al. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity[J]. Molecular Pharmaceutics,2014,Vol.11 No.7:2305-2312.
APA	Liu, M..,Li, W..,Larregieu, C.A..,Cheng, M..,Yan, B..,...&Mao, S.-J..(2014).Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.Molecular Pharmaceutics,Vol.11 No.7,2305-2312.
MLA	Liu, M.,et al."Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity".Molecular Pharmaceutics Vol.11 No.7(2014):2305-2312.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。